Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?

• Shinji Yamazaki,
• Raymond Evers,
• Loeckie De Zwart

Affiliations

Shinji Yamazaki

Drug Metabolism & Pharmacokinetics Janssen Research & Development, LLC San Diego California USA

Raymond Evers

Drug Metabolism & Pharmacokinetics Janssen Research & Development, LLC Spring House Pennsylvania USA

Loeckie De Zwart

Drug Metabolism & Pharmacokinetics Janssen Research & Development Beerse Belgium